Discover the latest in health and longevity on "Chrysea Insights". Dive into our pioneering research and innovations in precision nutrition that are setting new standards for a healthy lifespan.
Stay informed with the latest updates and breakthroughs from Chrysea. Explore our recent discoveries, news, milestones, and the impact we're making in the world of wellness and healthy nutrition.
Cantanhede, Portugal, New York City, USA and Dublin, Ireland; 10th January 2026 Chrysea Labs today announced a collaboration with Mount Sinai researchers who are Top 40 Milestone Award winners in the XPRIZE Healthspan, a $101 million global competition focused on advancing research on ageing and healthspan-related science. Miriam Merad, MD, PhD and Thomas Marron, MD, […]
Cantanhede, Portugal, Baltimore, USA and Dublin, Ireland; 30th September 2025 Chrysea a leading synthetic biology company focused on advancing breakthrough bioprocesses for health and longevity, today announced that it has entered into an exclusive licensing agreement with KaloCyte, Inc., a U.S. based biotechnology company developing innovative blood substitute solutions. Under this landmark deal, Chrysea […]
Cantanhede, Portugal and Dublin, Ireland; 18 April 2025 In 2024, Chrysea launched Sprevive® – a pure Spermidine formulation — the first in its pipeline of clean and sustainably produced as natural products, developed using a patented precision fermentation process and supported by extensive preclinical and clinical safety data. Extensive scientific research has long established the […]
Cantanhede, Portugal and Dublin, Ireland; 10 April 2025 In 2024, Chrysea launched Sprevive® – a pure Spermidine formulation — the first in its pipeline of clean and sustainably produced natural products, developed using a patented precision fermentation process and supported by extensive preclinical and clinical safety data. Extensive scientific research has long established the critical […]
Cantanhede, Portugal and Dublin, Ireland; 30 September 2024 A Chrysea sponsored randomized clinical study published in Nutrition Research is the first publication of a human study of high-purity (98%) spermidine. The study (NCT05459961) “Supplementation of Spermidine at 40 mg/day has Minimal Effects on Circulating Polyamines: An Exploratory Double-blind Randomized Controlled Trial in Older Men“ showed […]
Longevity supplements can be a valuable tool in supporting your aging journey. While they are not a magic bullet, these supplements should be seen as a complement to a healthy lifestyle, which includes a balanced diet, adequate sleep, and regular vigorous exercise. For those in the health industry aiming to reach consumers, it’s crucial to […]
Cantanhede, Portugal and Dublin, Ireland; 18 June 2024 Chrysea is proud to announce the launch of Sprevive®, the first of its pipeline of natural products sustainably produced using a patented precision fermentation process. Sprevive® is pure Spermidine, a bioactive naturally found in our diet, and now for the first time sustainably produced through precision […]
Acquisition of Rodon Biologics brings operational R&D capability, skilled talent, know-how, drives capital-efficiency, synthetic biology synergy in biopharma. DUBLIN, IRELAND, February 13, 2024 /EINPresswire.com/ — Chrysea Limited (“Chrysea”), has announced the acquisition of Rodon Biologics (“Rodon”) from Iberfar Group. Rodon is a company with over 20 years of expertise in biomanufacturing and development of biological products. […]
Researchers at Chalmers University of technology have developed an innovative yeast-based platform for producing Benzylisoquinoline alkaloids (BIAs) using synthetic biology techniques. Complex stereochemistry renders chemical synthesis of BIAs largely unfeasible. Synthetic biology and sophisticated microbial engineering coupled with recent advances in the elucidation of plant BIA metabolic networks has enabled the production of high-value BIAs by precision […]
Chrysea has been recognised as player of excellence having successfuly integrated the complete value-chain right from the laboratory to consumer and thus being able to provide novel precision ingredients to be used accross a variety of fields, ranging from precision nutraceuticals to products with biopharmaceutical applications. The BCG group estimates that synthetic biology manufacturing could […]
We discuss Chrysea’s future, both in terms of scaling the business, developing its polyamine products, their relations to aging and how through the digitalisation of biology the company is addressing a gap in the healthspan and wellness industries. In the second part of this interview, it discusses Chrysea’s future, both in terms of scaling the […]
Chrysea’s CEO explains more about the company, financial raises, Intellectual Property and its fit in the Longevity Biotech field. In the first of two interviews with Longevity Technology, Chrysea’s CEO explains more about the company, financial raises, Intellectual Property and its fit in the Longevity Biotech field.
Juvenescence Limited (“Juvenescence”), through its JuvLife Division, joins the 200M Fund portfolio, managed by Banco Português de Fomento, in the Venture Round investment in Chrysea Labs (“Chrysea”), a synthetic biology company developing high-value and difficult to source natural products, using proprietary synthetic biology platforms. Juvenescence and Chrysea will collaborate to develop and commercialise one of […]
A new peer reviewed scientific study carried out by the key co-founders of Chrysea, has been published in the prestigious journal Nature Catalysis and shows that baker’s yeast can be designed and optimised to produce polyamines and polyamine analogues for tackling grand challenges in both the health and agricultural sector. This ground breaking study describes […]
Chrysea Limited, was incorporated with the purpose to develop healthy-lifespan nutritional and supplementation interventions supported by rigorous clinical research, aimed at maintaining naturally occurring anti-ageing mechanisms such as autophagy. The company’s main technology is based on world-class synthetic biology capabilities spun-out of Professor Jens Nielsen’s labs at both the Technical University of Denmark (DTU) and […]